Exact Sciences Corporation struggles with profitability due to high expenses. See why EXAS stock faces challenges despite the ...

Early 2000s kids, listen up! Lil Jon is re-releasing a beloved beat to get you ahead of the game: "You can survive it if it's ...

Included was a final decision related to CMS pricing for Exact Sciences Corp’s (NASDAQ:EXAS) Cologuard Plus, a second-generation test that received FDA approval in October. William Blair writes ...

Janus Henderson Group PLC cut its holdings in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 14.1% in the 3rd quarter, ...

Lil Jon is back with a remix of his hit 2003 song “Get Low” — but this time, he’s using it to get people screened for colon cancer. “Get Low #2,” is part of a larger campaign by Exact Sciences to ...

Captrust Financial Advisors lifted its holdings in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 24.5% during the third quarter, according to the company in its most recent Form 13F filing with ...

Building on the success of the Cologuard ® and Oncotype ® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis.

Cancer is still among the leading causes of morbidity and mortality worldwide; in 2020, there were more than 19.3 million new ...